Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review

GlobalData
June 10, 2014
47 Pages - SKU: GBDT5280826
Lupin Limited (LUPIN) - Financial and Strategic SWOT Analysis Review

provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lupin Limited (Lupin) is transnational pharmaceutical company. The company focuses on the manufacture of generic and branded drugs, formulations and active pharmaceutical ingredients (API’s). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatric, GI, CNS, anti-infective, NSAID, Anti-TB and Cephalosporin segment. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. The company operates in India, the US, UK, Europe, Germany, Japan, South Africa, Philippines, and Australia.

Lupin Limited Key Recent Developments

May 07, 2014: Lupin Reports Its Performance For Fourth Quarter Ending 31st March, 2014
Apr 21, 2014: Lupin Appoints Theresa Stevens as Chief Corporate Development Officer
Mar 02, 2014: Lupin To Expand Its Dabhasa Facility In Vadodara, India
Feb 18, 2014: Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy
Feb 03, 2014: Lupin Strong Growth, Record Profits - Quarter III Results, FY 2013-14

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



More Pharmaceuticals Company reports by GlobalData

VistaGen Therapeutics , Inc. (VSTA) - Product Pipeline Analysis, 2014 Update by GlobalData
VistaGen Therapeutics , Inc. (VSTA) - Product Pipeline Analysis, 2014 UpdateSummaryVistaGen Therapeutics, Inc. (VistaGen) is a biopharmaceutical company. The company develops stem cell technology platform ...
Pierrel S.p.A. (PRL) - Financial and Strategic SWOT Analysis Review by GlobalData
Pierrel S.p.A. (PRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile ...
Pharmstandard (PHST) - Financial and Strategic SWOT Analysis Review by GlobalData
Pharmstandard (PHST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has ...
NuCana BioMed Limited - Product Pipeline Analysis, 2014 Update by GlobalData
NuCana BioMed Limited - Product Pipeline Analysis, 2014 UpdateSummaryNuCana BioMed Limited (NuCana) is a biopharmaceutical company. The company discovers, develops and commercializes anti-cancer medicines. It ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 125  
    Global Site License  USD 375  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!